Title:A New Approach for β-cyclodextrin Conjugated Drug Delivery System in Cancer Therapy
Volume: 19
Issue: 3
Author(s): Teng Meng Sheng and Palanirajan Vijayaraj Kumar*
Affiliation:
- Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, UCSI University, No. 1, Jalan Menara
Gading, Taman Connaught, Cheras, 56000 Kuala Lumpur, Malaysia
Keywords:
Cyclodextrin, cancer therapy, nanocarriers, hydrogel, inclusive compounds, theragnostic.
Abstract: Natural cyclodextrins (CDs) are macrocyclic starch molecules discovered a decade ago,
in which α-, β-, and γ-CD were commonly used. They originally acted as pharmaceutical excipients
to enhance the aqueous solubility and alter the physicochemical properties of drugs that fall under
class II and IV categories according to the Biopharmaceutics Classification System (BPS). The
industrial significance of CDs became apparent during the 1970s as scientists started to discover
more of CD’s potential in chemical modifications and the formation of inclusion complexes. CDs
can help in masking and prolonging the half-life of drugs used in cancer. Multiple optimization
techniques were discovered to prepare the derivatives of CDs and increase their complexation and
drug delivery efficiency. In recent years, due to the advancement of nanotechnology in pharmaceutical
sectors, there has been growing interest in CDs. This review mainly focuses on the formulation
of cyclodextrin conjugated nanocarriers using graphenes, carbon nanotubes, nanosponges, hydrogels,
dendrimers, and polymers to achieve drug-release characteristics specific to cells. These
approaches benefit the discovery of novel anti-cancer treatments, solubilization of new drug compounds,
and cell specific drug delivery properties. Due to these unique properties of CDs, they are
essential in achieving and enhancing tumor-specific cancer treatment.
